Eugia 3 OAI status may delay ANDA approvals
Eugia 3 plant classified as OAI; 29 pending ANDAs may be stuck for at least 1 year, impacting injectable growth.
high · analyst_question
Aurobindo Pharma Limited — Q4 FY24
Aurobindo Pharma delivered a strong Q4 FY24 with revenue of INR 7,850 crore (+17% YoY) and EBITDA of INR 1,687 crore (+68% YoY), driven by volume gains, new product launches, st...
bullish
high
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Biosimilar monetization timeline pushed to 2027-2028
Management expects meaningful biosimilar revenue only by 2027-2028, later than some investor expectations.
medium · management_commentaryPen-G ramp-up complexity may delay benefits
Pen-G fermentation is complex; yield optimization will only be addressed by September, posing execution risk.
medium · management_commentaryRyzneuta launch in US faces competitive pressure
Management is conservative on Ryzneuta (pegfilgrastim biosimilar) launch, citing multiple competitors and uncertain pricing.
medium · analyst_question